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Abstract
Background: Genetic variability is a major feature of the human immunodeficiency virus type 1 (HIV-1) and considered the
key factor to frustrating efforts to halt the virus epidemic. In this study, we aimed to investigate the genetic variability of
HIV-1 strains among children and adolescents born from 1992 to 2009 in the state of Sao Paulo, Brazil.
Methodology: Plasma and peripheral blood mononuclear cells (PBMC) were collected from 51 HIV-1-positive children and
adolescents on ART followed between September 1992 and July 2009. After extraction, the genetic materials were used in a
polymerase chain reaction (PCR) to amplify the viral near full length genomes (NFLGs) from 5 overlapped fragments. NFLGs
and partial amplicons were directly sequenced and data were phylogenetically inferred.
Results: Of the 51 samples studied, the NFLGs and partial fragments of HIV-1 from 42 PBMCs and 25 plasma were
successfully subtyped. Results based on proviral DNA revealed that 22 (52.4%) patients were infected with subtype B, 16
(38.1%) were infected with BF1 mosaic variants and 4 (9.5%) were infected with sub-subtype F1. All the BF1 recombinants
were unique and distinct from any previously identified unique or circulating recombinant forms in South America.
Evidence of dual infections was detected in 3 patients coinfected with the same or distinct HIV-1 subtypes. Ten of the 31
(32.2%) and 12 of the 21 (57.1%) subjects with recovered proviral and plasma, respectively, protease sequences were
infected with major mutants resistant to protease inhibitors. The V3 sequences of 14 patients with available sequences from
PBMC/or plasma were predicted to be R5-tropic virus except for two patients who harbored an X4 strain.
Conclusions: The high proportion of HIV-1 BF1 recombinant, coinfection rate and vertical transmission in Brazil merits
urgent attention and effective measures to reduce the transmission of HIV among spouses and sex partners.
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Introduction
Since the beginning of the HIV/AIDS pandemic, until the end
of 2010, over 3 million children under 15 years of age have been
infected with HIV-1 and 390,000 new viral infections each year
(most recent data from UNAIDS/WHO; http://www.who.int/
hiv/pub/progress_report2011/hiv_full_report_2011) have been
reported. Up until 2009, the Centers for Disease Control and
Prevention (CDC) estimates that perinatal transmission of the
infection by the mother accounts for 91% of all AIDS cases among
children under the age of 13 (CDC- Basic Statistics. Available at:
http://www.cdc.gov/hiv/topics/surveillance/basic.htm. Accessed
November 21, 2011). While mother to child transmission (MTCT)
has been drastically reduced (1–2%) in rich countries, pregnant
women living with HIV in poorer countries still have limited
access to the same quality of counseling and antiretroviral therapy
(ART) [1]. Therefore, these women are at higher risk of
transmitting the virus to their offspring during pregnancy, labor
or after childbirth via breastfeeding. Risk factors associated with
MTCT include lack of receipt of prenatal ART, advanced
maternal clinical status, detectable maternal viral load at delivery,
low maternal CD4 T cell counts, immunogenetic host factors, and
a high viral heterogeneity in the mother [2,3,4,5,6]. Without
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treatment, the chance of transmitting HIV from a mother to a
baby is somewhere between 12% and 25% in resource rich
settings, and between 20% and 45% in resource poor settings [7].
Although MTCT is being addressed by interventions of highly
active ART (HAART), which usually comprises three drugs, the
ultimate solution to HIV/AIDS will be a globally effective vaccine
to curb HIV from spreading further. However, the development of
such vaccines requires an in-depth knowledge of the virus strains
being transmitted in the target population.
One of the most prominent features of HIV-1 is the remarkable
accumulation of genetic diversity in its population during the
course of infection. This diversity reflects the high mutation rate of
reverse transcriptase (361025 substitutions per site per generation)
[8], rapid viral turnover (1028 to 1029 virions per day) [9], large
number of infected cells (107 to 108 cells) [10], and recombination
[11]. Consequently, the HIV-1 population is composed of a swarm
of highly genetically related variants, i.e. a quasispecies, capable of
rapidly adapting to various selective pressures. This diversity has
been shown to have an impact not only on viral phenotypes at the
level of transmission patterns, pathogenicity and immunology but
also in responses to ART and vaccines [12,13,14]. Nine distinct
genetic subtypes, (A–D, F–H, J and K) are joined in the pandemic
today by more than 50 major circulating recombinant forms
(CRFs) [http://www.hiv.lanl.gov/content/sequence/HIV/
CRFs/CRFs.html] and numerous unique recombinant forms
(URFs) have been isolated from individual patients [15,16].
Brazil, the most populous country in the Latin America, is home
to about one third of the people living with HIV (608,230) in
Central and South America (UNAIDS. 2010–2011 Report on
the Brazilian response to HIV/AIDS; http://www.unaids.org/
en/dataanalysis/knowyourresponse/countryprogressreports/2012
countries/UNGASS_2012_ingles_rev_08jun.pdf). According to
2008 estimates from UNAIDS (most recent data), 13,728 cases
of HIV-infected Brazilian children were notified and 84.5% of
them were infected by vertical transmission. Despite the
availability of free HIV diagnostic tests and ART, perinatal
transmission of HIV-1 infection by the mother remains a national
public health challenge in some areas, where difficulties in
providing the requisite antenatal HIV screening exist. Like in
other European countries and in North America, HIV-1 subtype B
is a major genetic clade circulating in the country but the overall
prevalence of non-B strains, particularly URF BF1, C and URF
BC, is increasing [17,18,19,20]. Data from recent studies of the
viral near full length genomes (NFLG) have provided evidence of
Brazilian CRF strains designated as CRF28_BF, CRF29_BF,
CRF39_BF, CRF40_BF, CRF46_BF and CRF31_BC
[18,19,21,22] (http://www.hiv.lanl.gov/content/sequence/HIV/
CRFs/CRFs.html.). However, most HIV molecular variability
studies in Brazil so far have been limited to adult patients and/or
are based on sequence information derived from small genetic
fragments that may not predict the subtype classification of other
regions of the viral genomes.
Unlike HIV-1 infection in adults, multiple HIV-1 strains are not
expected to co-circulate in children and the precise timing of the
transmission event can be traced to the time of birth, providing a
unique opportunity to explore the viral evolution [23].
The present study was undertaken to describe the genetic
variability and identify resistance-associated mutations in HIV-1
isolates recovered from children, adolescents, and young adults
with majority perinatally acquired HIV infection.
Materials and Methods
Study Population
A cross sectional study was conducted among 51 HIV-1 infected
children (ages 0–14 years) and adolescents (aged 15–20 years) on
ART followed between September 1992 and July 2009 at the
Division of Pediatric Infectious Disease Clinic (CEADIPe), at the
Federal University of Sa˜o Paulo (UNIFESP), Brazil. All, but three
of the participants had been born to HIV-1 seropositive mothers.
From their medical records, almost all of the seropositive mothers
had multiple sexual partners or had an exclusive sexual
relationship with a partner whom they knew either to have had
other sexual partners or, less commonly, to have a history of
injection drug use. Three participants were born to women
seronegative for HIV-1 and thus had an unknown transmission
mode of their infection. All study participants gave written
informed consent. Parents or legal guardians provided written
informed consent on behalf of the children. The study plan and
consent procedures were approved by the ethics committee of the
federal University of Sa˜o Paulo.
Amplification & Sequencing
Proviral DNA and RNA were extracted from peripheral blood
mononuclear cells (PBMC) and plasma with commercial kits
(QIAamp DNA Blood mini Kit and QIAamp Viral RNA Kit,
QIAGEN, Germany) according to the manufacturer’s instructions.
To make complementary DNAs, the extracted RNA samples were
subjected to reverse transcription PCR using SuperScript III
(Invitrogen, Carlsbad, CA). Both cDNAs and proviral DNAs were
Table 1. Patient characteristics for the study population.
Age, median (range) years 11.5 (4–20)
Gender (%)
Male 21 (41.2)
Female 30 (58.8)
Race (%)
White 32 (69.6)
Black 6 (13)
colored 8 (17.4)
Undetermined 6 (13)
HIV RNA level, median (range) 6.346102
(,4927.56105)
Current HIV RNA ,50 (%) 19 (36.5)
Current HIV RNA .50 (%) 33 (63.5)
CD4 cell count (cells/mm3), Median (range) 640 (18–1821)
CD8 cell count (cells/mm3), Median (range) 1052 (212–2377)
Antiretroviral therapy exposure
Naı¨ve (%) 4 (7.7)
Previous exposure (%) 2 (3.8)
Unkown status 1 (1.9)
Receiving antiretroviral therapy (%) 45 (86.6)
Treatment regimen at the time of enrollment
Combined NRTIs+PI (%) 28 (62.2)
Combined NRTIs (%) 4 (8.9)
Combined NRTIs+NNRTI (%) 9 (20)
NRTI+NNRTI+ PI (%) 3 (6.6)
NRTI+PI (%) 1 (2.3)
doi:10.1371/journal.pone.0062552.t001
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Table 2. The near full-length genomic (NFLG) and partial fragments subtyping of HIV-from plasma and blood samples.
Sequence ID Sample Age/yrs Sequence fragment Subtype VL*
A (546–2598) B1 (2157–3791) B2 (3236–5220) C (4890–7808) D (7719–9537)
010BR_001 PBMC 20 – – – – –
Plasma – – – – – 49
010BR_002 PBMC 14 – – – – –
010BR_IMT_002_pl Plasma – + – – – BF1 7433
010BR_003 PBMC 19 – – – – –
010BR_IMT_003_pl Plasma
010BR_004 PBMC 17 – – – – –
010BR_IMT_004_pl Plasma
010BR_005 PBMC 7 + + – + + BF1
010BR_IMT_005_pl Plasma – – – – – 5473
010BR_006 PBMC 11 – + – + + BF1
010BR_IMT_006_pl Plasma + – – + – BF1 1543
010BR_007 PBMC 11 – – – + – B
010BR_IMT_007_pl Plasma – – – – – 49
010BR_008 PBMC 11 – – – – –
010BR_IMT_008_pl Plasma – – – – – 49
010BR_009 PBMC 8 + – – + + B
010BR_IMT_009_pl Plasma + – – – – B 1879
010BR_010 PBMC 13 – + – – – B
010BR_IMT_010_pl Plasma – + – – – B 49
010BR_011 PBMC 10 – + – – – F1
010BR_IMT_011_pl Plasma + – – – – BF1 1452
010BR_012 PBMC 10 – – – – + B
010BR_IMT_012_pl Plasma – – – – – 29361
010BR_013 PBMC 12 – – – + – BF1
010BR_IMT_013_pl Plasma + – – – – B 560
010BR_014 PBMC 11 – – – – –
010BR_IMT_014_pl Plasma + – – – – F1 1858
010BR_015 PBMC 11 + – – – – B
010BR_IMT_015_pl Plasma + – – + – B 3859
010BR_016 PBMC 7 + + – + – BF1
010BR_IMT_016_pl Plasma + + – – – B 33650
010BR_017 PBMC 18 – – – + + B
010BR_IMT_017_pl Plasma – – – + – B 39153
010BR_018 PBMC 15 + – – – – B
010BR_IMT_018_pl Plasma – – – – – 49
010BR_019 PBMC 11 + – – – – B
010BR_IMT_019_pl Plasma + – – – – B 1209
010BR_020 PBMC 14 + + + + + B
010BR_IMT_020_pl Plasma – – – + – B 572
010BR_021 PBMC 12 + – – – + B
010BR_IMT_021_pl Plasma – – – – – 87
010BR_022 PBMC 10 + – – + – BF1
010BR_IMT_022_pl Plasma – – – – – 49
010BR_023 PBMC 10 – – – – –
010BR_IMT_023_pl Plasma – – – – – 49
010BR_025 PBMC 13 – – – + + BF1
010BR_IMT_025_pl Plasma – – – – – 49
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Table 2. Cont.
Sequence ID Sample Age/yrs Sequence fragment Subtype VL*
A (546–2598) B1 (2157–3791) B2 (3236–5220) C (4890–7808) D (7719–9537)
010BR_026 PBMC 11 + + + + + BF1
010BR_IMT_026_pl Plasma + – – + – B 37134
010BR_027 PBMC 7 + – – – + B
010BR_IMT_027_pl Plasma – – – + – B 10038
010BR_029 PBMC 14 + + – – + BF1
010BR_IMT_029_pl Plasma – – – – – 49
010BR_030 PBMC 15 – – – – + BF1
010BR_IMT_030_pl Plasma – – – – – 49
010BR_031 PBMC 15 + – – – – F1
010BR_IMT_031_pl Plasma – – – – – 49
010BR_032 PBMC 13 – + + – – B
010BR_IMT_032_pl Plasma – + + + – B 7824
010BR_033 PBMC 10 + – – – + B
010BR_IMT_033_pl Plasma – – – – – 49
010BR_034 PBMC 10 + + – – – B
010BR_IMT_034_pl Plasma + – – – – B 13391
010BR_035 PBMC 14 – – – – + BF1
010BR_IMT_035_pl Plasma + + + + + BF1 35172
010BR_036 PBMC 18 – – – + + B
010BR_IMT_036_pl Plasma + – – – + B 17292
010BR_037 PBMC 4 + – – – – B
010BR_IMT_037_pl Plasma + – – – – B 697
010BR_038 PBMC 11 – – – – + B
010BR_IMT_038_pl Plasma – – – – – 365
010BR_039 PBMC 12 + – – – + B
010BR_IMT_039_pl Plasma + – – – – B 83187
010BR_040 PBMC 16 – + – – – BF1
010BR_IMT_040_pl Plasma – – – – – 49
010BR_041 PBMC 9 + + + + + F1
010BR_IMT_041_pl Plasma + + + + – BF1 5411
010BR_042 PBMC 10 + + + – + BF1
010BR_IMT_042_pl Plasma + + – – – B 13213
010BR_043 PBMC 9 – – – + – B
010BR_IMT_043_pl Plasma – – – – – 49
010BR_044 PBMC 19 – + + + – B
010BR_IMT_044_pl Plasma – – – – – 750000
010BR_045 PBMC 14 + – – + + BF1
010BR_IMT_045_pl Plasma – – – – – 49
010BR_046 PBMC 6 + – – – + BF1
010BR_IMT_046_pl Plasma – – – – – 139
010BR_047 PBMC 11 + + + + + F1
010BR_IMT_047_pl Plasma + + + + – F1 15556
010BR_048 PBMC 13 – – – – –
010BR_IMT_048_pl Plasma + – – – + F1 10365
010BR_049 PBMC 14 – + + – + BF1
010BR_IMT_049_pl Plasma – – – – – 49
010BR_051 PBMC ND
010BR_IMT_051_pl Plasma – – – – + B 49
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Table 2. Cont.
Sequence ID Sample Age/yrs Sequence fragment Subtype VL*
A (546–2598) B1 (2157–3791) B2 (3236–5220) C (4890–7808) D (7719–9537)
010BR_054 PBMC 13 – + – – + B
010BR_IMT_054_pl Plasma – – – – – 24453
010BR_056 PBMC 11
010BR_IMT_056_pl Plasma – – – – – 49
010BR_057 PBMC 13 + + – – + B
010BR_IMT_057_pl Plasma – – – – – 49
010BR_058 PBMC 14 + + – – – BF1
010BR_IMT_058_pl Plasma – – – – – 1671
010BR_060 PBMC 12 – – – – –
010BR_IMT_060_pl Plasma – – – – – 126
*VL – Viral Load (copies/mL).
doi:10.1371/journal.pone.0062552.t002
Figure 1. Schematic representation of the NFLG, partial structure and breakpoint profiles of the BF1 sequences identified in this
study both from HIV RNA and proviral DNA. Samples that were identified in this study to host distinct viruses are indicated with the star
symbol. The region of subclade F1 and subtypes B are indicated at the bottom.
doi:10.1371/journal.pone.0062552.g001
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Figure 2. Genetic distances of overlapping regions between isolates recovered from patients with paired plasma and PBMC
samples. Concatenated sequences are indicated with the star symbol. The region of subclade F1 and subtypes B are indicated at the bottom.
doi:10.1371/journal.pone.0062552.g002
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used as the PCR template, as this allowed amplification of the
NFLGs from five overlapping fragments as previously described
[24,25,26]. Amplification reactions were done in duplicate to
eliminate PCR artifacts, ensuring that sequenced full-length
genomes were not assembled from heterogeneous DNA targets.
The expected sizes of the amplified products were verified using
ethidium-bromide staining after agarose gel electrophoresis. Each
PCR included a known HIV-1 subtype B positive control and an
interspersed no DNA template negative controls. Strict laboratory
precautions were taken to avoid cross contamination.
Both DNA complementary strands were sequenced directly
from purified PCR products in an overlapping fragment of 400
nucleotides by using a variety of sequence specific primers,
fluorescent-dye terminators, and Taq polymerase on an automated
sequencer (ABI 3100, Applied Biosystems Inc., Foster City, CA).
The data from the sequenced fragments were edited, assembled
into contiguous sequences on a minimum overlap of 20 bp with a
Figure 3. Maximum-likelihood phylogenetic trees form each non-recombinant fragment were constructed using all available
sequences from proviral DNA (indicated by black circles) and plasma isolate (indicated by an empty circles) along with HIV-1
reference sequences from the Los Alamos HIV-1 database representing 11 genetic subtypes. The numbering for the HIV-1 fragment A,
B1, B2 and C sequences corresponds to the HXB2 reference sequence. For purposes of clarity, the tree was midpoint rooted. The approximate
likelihood ratio test (aLRT) values of $70% are indicated at nodes. The scale bar represents 0.05 nucleotide substitutions per site.
doi:10.1371/journal.pone.0062552.g003
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85%–90% minimal mismatch and a consensus of both strands was
formed by the Sequencher program (Gene Code Corp., Ann
Arbor, MI). Such assembly criteria would prevent any fragment
from overlapping if it is not derived from the same variant. All the
sequences were checked for contamination by BLAST search
against HIV-1 sequence database and among themselves [27].
Phylogenetic Analysis
Full genome sequences were aligned with reference sequences
representing subtypes A–D, F–H, J and K obtained from the Los
Alamos database (http://hiv-web.lanl.gov) using the CLUSTAL
X program [28] with the ‘‘slow-accurate’’ default alignment
parameters and IUB DNA weight matrix. Aligned sequences were
manually edited and trimmed to the minimal shared length in the
BioEdit Sequence Alignment Editor Program. The gap-stripped
aligned sequences were screened for the presence of recombina-
tion patterns by the bootscan methods implemented in the
SIMPLOT program v3.2 beta [29,30] and the jumping profile
Hidden Markov Model [31]. For the bootscan method, nucleotide
distances were calculated in a sliding window of 300 bp moving in
steps of 30 bp by the F84 model of evolution, transition\transver-
sion ratio of 2.0. Recombinant regions of the alignment as
determined by the crossover points from bootscanning were
analyzed separately by phylogenetic analysis. Maximum likelihood
phylogenies were constructed using the GTR+I+G substitution
model and a BIONJ starting tree. Heuristic tree searches under
the ML optimality criterion were performed using the NNI
branch-swapping algorithm. The approximate likelihood ratio test
(aLRT) based on a Shimodaira-Hasegawa-like procedure was used
as a statistical test to calculate branch support. The maximum
Figure 4. Genetic distances and phylogenetic tree constructed using a maximum-likelihood method from concatenated regions of
HIV RNA (indicated by black circles) and proviral DNA (indicated by black squares) marked with Arabic numbers 1 and 2 from
patient 010BR_IMT_020 along with HIV-1 reference sequences from the Los Alamos HIV-1 database representing 11 genetic
subtypes. For purposes of clarity, the tree was midpoint rooted. The approximate likelihood ratio test (aLRT) values of$70% are indicated at nodes.
The scale bar represents 0.05 nucleotide substitutions per site.
doi:10.1371/journal.pone.0062552.g004
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composite likelihood in MEGA version 4 [32] was used to
calculate the genetic distances between and within isolates.
Genotyping Analysis
All amino acid positions associated with ART resistance, in the
protease (Pro) and reverse transcription (RT) regions, according to
IAS-USA 2011 and Stanford HIV drug resistance database were
evaluated on both plasma and blood samples.
Measurement of HIV RNA and Cell Count
The viral load was measured using the Roche Amplicor HIV-1
Monitor test (Roche, Branchburg, NJ; lower limit of detection 50
copies per ml). CD4+ and CD8+ T cell counts were performed
using a lymphocyte staining panel containing CD3, CD4, CD8,
and CD45 conjugated monoclonal antibodies (BD Biosciences,
San Diego, California, USA).
Genotypic Tropism Analysis
For the predictions of HIV tropism, the env region identified in
the NFLGs and partial-length env sequences that would encompass
the V3 region were analyzed using a tropism prediction algorithm
implemented as the web-based service geno2pheno [coreceptor]
http://www.geno2pheno.org. To minimize the number of false
predictions of CXC chemokine receptor 4 (CXCR4 or X4) tropic
sequences as C–C chemokine receptor 5 (CCR5 or R5) tropic, a
conservative false-positive rate (FPR) of 20% was used as a cutoff.
Therefore, X4 or X4 dual/mixed-tropic viruses (X4/DM) were
reported positive if their sequences had a prediction result FPR of
#20% or the 11/25 rule predicted a X4 virus, otherwise, they
were considered R5-tropic viruses.
All nucleotide sequences obtained during our study were
reported to GenBank (Accession numbers pending).
Results
Samples
In total, 49 paired samples of whole blood and plasma and 2
unpaired samples of each type from an additional 4 different
patients were subjected to NFLG amplification and sequencing.
Of these 51 subjects, 21 (41.2%) were males and 30 (58.8%) were
females. The participants were predominantly white (69.6%), were
Figure 5. Genetic distances and phylogenetic tree constructed using a maximum-likelihood method of HIV isolates recovered from
patient 01BR_IMT_041. A: Phylogenetic tree from concatenated regions assigned as subtype B from the BF1 recombinant isolate. B: Phylogenetic
tree showing the clustering pattern of F1 sequences (marked by dotted box). F1 region from genuine F1 sequence recovered from plasma and
PBMCs are marked by a black circle and square, respectively while the F1 region from the BF1 recombinant sequence is marked by an empty square.
The approximate likelihood ratio test (aLRT) values of $70% are indicated at nodes. The scale bar represents 0.05 nucleotide substitutions per site.
doi:10.1371/journal.pone.0062552.g005
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followed from birth and reached a median age of 11.5 years (range
between 4 and 20 years). The median HIV-1 viral load and CD4
cell count, as judged by levels at the time of inclusion, were
6.346102 copies/ml (range, 4927.56105) and 640 cells/mm3
(range, 18–1821 cells/mm3), respectively. Four (8%) patients were
naı¨ve and an additional 2 (4%) patients were not taking therapy at
the time of enrollment, although they were drug-experienced. The
therapeutic status was not known for one subject. Among the 43
subjects, 69.7% had received $3 different ART regimens during
their follow-up. The median duration of ART at the time of
genotyping was 27.5 months. The main characteristics and ART
regimens of the study population are given in Table 1.
NFLG and Partial Amplification of HIV-1 from both PBMC
and Plasma Specimens
Sequences were obtained for all five overlapped fragments that
cover the NFLGs of 4 PBMC DNA and one plasma RNA virus.
Partial sequences were obtained from at least one fragment
derived from 38 blood and 24 plasma samples as shown in Table 2.
Of the 26 plasma samples for which partial and NFLGs failed, 21
(80.7%) had a viral load under 500 copies/ml and the remaining 5
(19.3%) RNA viruses had multiple peaks present in the sequencing
chromatogram probably indicating different quasispecies in the
same sample or HIV-1 dual infections. On the other hand, partial
amplification of 1126 bp of fragment B1(Nucleotide position from
start of HXB2 genome 2196–3322) and 494 bp stretch of
fragment D (Nucleotide position from start of HXB2 genome;
8997–9491) were subtype B positive for isolates 010BR_IMT_010
and 010BR_IMT_051, respectively, and both patients had viral
loads below 50 copies/ml (Table 2). These results may suggest an
underestimation of the measured viremia or high efficacy of our
nested PCR approach in some patients. On the other hand, our
results among paired samples demonstrated that 20 patients had
detectable HIV proviral DNA and undetectable viral RNA, 21
were dually positive for viral RNA and DNA, and 4 patients were
dually negative. It is unclear why we were unable to amplify more
plasma RNA viruses, particularly for patients 010_BR_IMT_05,
010_BR_IMT_12, 010_BR_IMT_54, and 010_BR_IMT_58
(median viral load 1.56104, range 1.66103–2.96104) using our
fragment-based amplification strategy, although RNA degradation
may account for this finding.
HIV Variants and Sequences
Based on phylogenetic analysis, the NFLGs and partial proviral
nucleotide sequences (n = 42) of the clinical HIV-1 isolates
indicated that 22 (52.4%) patients were infected with HIV-1
subtype B, 16 (38.1%) were infected with a mosaic consisting of
subtype BF1 and 4 (9.5%) were infected with sub-subtype F1
(Table 2). Of the total 25 plasma samples for which viral subtype
was determined, 17 (68%) were classified as subtype B, 3 (12%)
Figure 6. Phylogenetic clustering profile of the non-overlapped fragments assigned as subtype B from both plasma and provirus
isolate 01BR_IMT_013 were compared to a number of additional Brazilian subtype B sequences and other HIV-1 reference
sequences from the Los Alamos HIV-1 database representing 11 genetic subtypes. For purposes of clarity, the tree was midpoint rooted.
The approximate likelihood ratio test (aLRT) values of $70% are indicated at nodes. The scale bar represents 0.05 nucleotide substitutions per site.
doi:10.1371/journal.pone.0062552.g006
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were sub-subtype F1, and 5 (20%) were BF1 recombinant viruses
(Table 2). All chimeric viruses were unique according to their
recombination profile, i.e., not assigned to any subtype or CRF
(Figure 1). The relationships of the viral sequences from patients’
PBMCs to the sequences obtained from the corresponding RNA
virus within the same regions were examined for each patient to
assess the viral diversity in both compartments. The results
revealed that all but one patient, 010BR_IMT_020, had plasma
RNA and proviral DNA variation only ranging between 0–2.7%
(Figure 2). These relations were further confirmed by phylogenetic
analysis, which showed close branching as demonstrated in
Figure 3. These findings may indicate that the primary infected
PBMCs of these patients were likely the source of plasma
circulating viral sequences however; more sophisticated genetic
tests able to detect viral population structure are needed to confirm
this conclusion. The observed differences in the percent nucleotide
variations between proviruses and plasma free viruses in this group
may reflect evolution that occurs during the initial phase of acute
infection, before the therapeutic control of HIV-1 replication is
established. Surprisingly, the intra-individual plasma and proviral
sequence variation for patient 010BR_IMT_020 in the overlapped
regions depicted in Figure 4 were 9.8% and 6.5%, respectively,
indicating that the plasma viruses were derived from a population
significantly distinct from those of the cellular sources in this 13
years old asymptomatic patient. This result is consistent with dual
distinct variants of the same subtype being involved in establishing
infection. Dual infection with subclade F1 and BF1 recombinant
was observed in patient 010BR_IMT_041 plasma sample
(Figure 5). This patient was a nine year old child who diagnosed
in February 2005 and until the sampling period had been
asymptomatic. The patient had been receiving ART since
September 2005. This observation of dual infection occurred
accidentally during assembling of the generated data, in which
some sequences failed to assemble to other overlapping stretches of
fragment B1. As a result, we sought to compare this stretch to HIV
sequences available from public databases. Upon analysis with the
basic local alignment search tool (BLAST) available from
GenBank, the stretch (010BR_IMT_041_PL- REC; 548 bp) from
plasma revealed high percentages of nucleotide sequence identity
to the BF1 isolate 99JY-TRA0133 (Genbank accession:
JN235964), whereas the other larger fragment
(010BR_IMT_041_pl; 5720 bp) revealed high homology to
subclade F1 isolate 02BR082 (Genbank accession: FJ771006) at
the nucleotide levels. To ensure that the generation of the two
Table 3. Drug-resistance mutations detected in plasma.
Sample ID Resistance mutations HIV-1 subtypeTropism CV*
PI NRTI NNRTI
010BR_IMT_002 M36I M184V BF1 7433
010BR_IMT_006 L10V, K20R, M36I, I54V, L63P, A71V,
V82A, L90M
BF1 R5 1543
010BR_IMT_009 K20T, M36I, I62V, L63P, I64V,
V82I, L90M
B 1879
010BR_IMT_011 L10V, K20R, L24I, M36I, M46L, I54V,
L63P, V82A
BF1 1452
010BR_IMT_013 I64V, V77I, V82I B 560
010BR_IMT_014 M36I, L89M F1 1858
010BR_IMT_015 M36I B R5 3859
010BR_IMT_016 L63P B 33650
010BR_IMT_019 D60E, I62V, L63P, I64V B 1209
010BR_IMT_026 M36I, L63P B R5 37134
010BR_IMT_032 D60E, L63P, H69K, V77I M184V B R5 7824
010BR_IMT_034 L10V, V32I, L33F, K43T, M46I, I54V,
L63P, A71V, V82A, L89V, L90M
B 13391
010BR_IMT_035 L10V, K20T, M36I, I62V, L63P, L89I,
L90M, I93L
M41L, A62V, V75I, F116Y,
Q151M, K65R
G190A BF1 X4 35172
010BR_IMT_036 L10I, L33F, M36I, I54V, Q58E, D60E,
I62V, I64V, L76V, V82A, L89M
B 17292
010BR_IMT_037 I62V, I64V B 697
010BR_IMT_039 L63P, A71V, V77I, I93L B 83187
010BR_IMT_041 L10V, K20R, M36I, M46I, I54V, I62V,
L76V, V82A, L89M
M41L, L74V,
M184V, T215Y
K103N F1 5411
010BR_IMT_042 L10I, K20R, M36I, Q58E, D60E, L63P,
A71V, V82A, L90M, I93L
B 13213
010BR_IMT_047 L10V, M36I, L89M K103N F1 R5 15556
010BR_IMT_048 M36I, I64V F1 103665
*copies/Ml.
Regions not sequenced are indicated by empty boxes.
High resistance mutation are indicated by bold lettering.
doi:10.1371/journal.pone.0062552.t003
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consensus sequences from patient 010BR_IMT_041 plasma
sample was not the result of sample contamination, repeat
sequence analysis using the purified B1 amplicon was performed
and revealed identical findings. These results possibly indicate that
some internal sequencing primers of fragment B1 preferentially
annealed to the BF1 string during sequencing reaction. Regions
that were the same F1 subclade in the two pols were then
compared to determine whether the 010BR_IMT_041_PL viruses
were the actual parents of the recombinant fragment or if an
infection in this patient was acquired with two genetically distinct
viruses (Figure 5B). While both partial pol genes were sub-subtype
F1 fragments, these were from different subclade F1 isolates, since
the sequences from the two plasma demonstrated high nucleotide
divergence (up to 6.8%). Moreover, as shown in Figure 5B, both
F1 non-recombinant sequences recovered from plasma and
PBMC clustered separately (aLRT 100%) and the branch lengths
separating them from the F1 fragment involved in the recombi-
nation event were typical for other sequences of unrelated F1
variants. The analysis was then extended to include isolates with
non-overlapping fragments, namely 010BR_IMT_013 and
010BR_IMT_027, to determine whether the PBMC viruses were
truly parental strains to those recovered from the plasma. For this
Table 4. Drug-resistance mutations detected in PBMC.
Sample ID Resistance mutations HIV-1 subtype Tropism
PI NRTI NNRTI
010BR_IMT_005 L10V, L20R, M36I M41L, T215Y BF1 R5
010BR_IMT_006 I54V, V82A, L10V, L20R, M36I,
L63P, A71V, I93M
M41L,V75M, M184V, T215Y K103N, A98G,
V108I, H221Y
BF1 R5
010BR_IMT_009 K20T, M36I, I62V, L63P, I64V,
V82I, L90M
B R5
010BR_IMT_0111 L24I, I54V, V82A, L90M, L10I,
L20R, M36I, L63P
D67G,K70R, M184V F1
010BR_IMT_015 M36I B
010BR_IMT_016 M36I, L63P G190A, E138A BF1 R5
010BR_IMT_018 M36I, I64V, H69K B
010BR_IMT_019 D60E, I62V, L63P, I64V B
010BR_IMT_020 M36I, M46I B R5
010BR_IMT_021 I64V B
010BR_IMT_022 I64V BF1 R5
010BR_IMT_026 M36I, L63P M41L,T215C BF1 R5
010BR_IMT_027 A71V, V77I, I93L B
010BR_IMT_029 V82A, L20R, M36I D67N, K70R, M184V BF1
010BR_IMT_031 M36I, L63P F1
010BR_IMT_032 D60E, L63P, H69K, V77I M184V B
010BR_IMT_033 G16E, L33V, I62V, V77I B
010BR_IMT_034 I30V,M46I, I54V, V82A,
L33F, A71V
D67N, K70R, L210W, T215Y B
010BR_IMT_037 I62V, I64V B
010BR_IMT_039 L63P, A71V, V77I, I93L B
010BR_IMT_040 D30N, M46I, I54V, L76V, V82A,
L90M, L10I, L20R, M36I, I62V
M41L, D67N, M184V E138K BF1
010BR_IMT_041 M46I,I54V, L76V, V82A, L10V,
L20R, M36I
M41L, L74V, V75M, M184V,
T215Y
K103N F1 X4
010BR_IMT_042 I54L, V82A, L90M, L10I, M36I,
Q58E, D60E, L63P, A71V, V77I, I93L
M41L, D67N,L74I, V75T Y181C BF1
010BR_IMT_045 M36I BF1 R5
010BR_IMT_046 M36I BF1
010BR_IMT_047 M46I, L10V, M36I F1 R5
010BR_IMT_049 I64V, V77I, I93L L210W, T215Y Y181C BF1
010BR_IMT_054 L90M, L20I, M36I, L63P, A71T M41L, M184V, T215Y L100I, K103N B
010BR_IMT_057 D30N, M36I, L63P B
010BR_IMT_058 M36I, D60E, I62V, I64V M41L, M184V, T215Y K103N,P225H,
E138A
BF1
1Displayed insertion at position 69.
Regions not sequenced are indicated by empty boxes.
High resistance mutations are indicated by bold lettering.
doi:10.1371/journal.pone.0062552.t004
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purpose, the phylogenetic clustering profile of the non-overlapped
fragments from both compartments were compared to a number
of additional Brazilin subtype B and other HIV-1 reference
sequences to increase our confidence in the analyses and provide a
broader perspective. These results revealed the magnitude of
aLRT value supporting the identical clustering of the plasma
isolate 010BR_IMT_013_pl (Figure 6A) and the proviral
010BR_IMT_013_pr strains (Figure 6B) with the Brazilian
subtype B BREPM 1040 and 05BR 1092 subtype B sequences
(branch marked with green color). Based on these results, it is
possible to assume that the primary infected PBMCs in this patient
were likely the source of the plasma circulating viral sequences.
However, this interpretation does not hold true when the analysis
was applied to the plasma and proviral non-overlapping fragments
of patient 010BR_IMT_027. The clustering profile to subtype B
references and genetic distances as shown in Figure S1 were
significantly different between both fragments in this patient
indicating dual infection with distinct subtype B variants.
Genotypic Drug Resistance Test Results
The results of the genotyping analysis from both plasma RNA
and whole blood DNA are presented in Table 3 and 4. Resistance
analyses were performed from proviral DNA in 32 patients (19
PR/RT and 13 PR) and from plasma-associated RNA in 21
patients (8 PR/RT and 13 PR). Regardless of paired or unpaired
samples, 10 of the 31 (32.2%) and 12 of the 21 (57.1%) subjects
with recovered proviral and plasma PR sequences, respectively,
were on ART at the time of specimen collection and were infected
with major mutants resistant to protease inhibitors (PIs). Regard-
ing the primary resistant mutations for PIs among the naive
patients with available PR sequences from PBMCs (n = 4) and
plasma (n = 3), various mutations were detected in only one patient
(010BR_IMT_034; Table 3 and 4). The RT region of the provirus
of the same patient displayed some major transmitted mutations
both for the NRTIs and NNRTIs. Detailed frequency of single Pro
and RT mutations detected in patients on ART both in plasma
RNA and whole blood DNA is also illustrated in Table 3 and 4.
V3 Sequence Analysis and Viral Tropism
An evaluation of the V3 loop amino acids and predictions of
viral tropism were performed for patients with available sequences
from PBMCs (n = 10) and plasma (n = 7) of the derived fragment C
intact frame sequences. The inferred HIV tropism in paired
samples of plasma and PBMCs was successfully determined in 3
samples and all concordant with the R5 virus. The inferred HIV
tropism study in the other 3 plasma demonstrated that 2 patients
harbored the R5 virus. The V3 sequences of the 7 patients with
available sequences from only PBMC were predicted to be R5-
tropic virus except for patient 01BR_IMT_035 who harbored an
X4 strain.
Discussion
This study describes the genetic variability and the prevalence of
drug resistance mutations and co-receptor usage of HIV-1 variants
in a small, well sampled group of children and adolescents. The
majority of these patients acquired their infection through vertical
transmission during the period 1992–2007. The results presented
confirmed that subtype B is still the main HIV-1 variant and
concordant with data from other studies on adult and children
populations from Brazil [24,33,34,35]. The most remarkable
observations in this study are that at least 38.1% of the 42 patients
with proviral DNA sequences are infected with HIV-1 BF1
recombinant variants, which is relatively much higher if compared
to earlier studies on children and adolescent patients in Brazil
[33,34,35,36,37,38]. This difference is not surprising, because
small fragments from different regions of HIV genomes were
characterized in the previous studies while we used larger
overlapped fragments to sequence the full-length genome, which
undoubtedly provides efficient discrimination of HIV subtypes and
the recombinant forms. Thus, the earlier study is likely to have
missed some recombinants. Despite the high rate of recombination
in our study, it is probable that our results have also underesti-
mated the true rate of infection with BF1 recombinant viruses,
particularly among patients with partially sequenced viral
fragments. Thus, it is possible that the BF1 infection in this group
may be higher than what was observed if we had sequenced the
virus NFLG in all samples. Our attempts to amplify the NFLG or
additional larger fragments for some samples to determine if
recombination had occurred were unsuccessful. Other likely
explanations for underestimation of BF1 recombination rate is
that some isolates could have been undetected by our PCR
strategy because of a mismatch at the primer binding sites, low
proviral load, employment of consensus sequences or that the BF1
isolates were maintained in another reservoir other than the CD4-
positive compartment that was sampled in the peripheral blood.
The results that indicate none of the BF1 recombinant structures
identified in this study showed any similarity to the known CRFs
or other recombinants strongly suggests that new recombinants are
arising continually in Sa˜o Paulo, Brazil.
Additional observations of this study are the description of the
high level of intra-host diversity with evidence of mixed infections
with the same or distinct HIV-1 subtypes. The observation that
patients may be simultaneously infected with different HIV-1
subtypes has been reported in numerous cases and considered of
significant interest. For instance, the first documented dual
infection of two distinct HIV-1 subtypes B and E (later designated
as CRF01_AE) was reported in Thailand [39]. Janini et al. [40]
reported the first case of both horizontal and subsequent vertical
transmission of 2 distinct HIV-1 subtypes from 1 dually infected
person to another. In the present study, dual infections were
evident in three patients, lending further support to previous
studies [41,42,43], as this event is far more common in Brazil
where both subtypes co-circulate. The fact that existence of dual
infection in some patients contrasts with the hypothesis that an
initial viral infection produces some degree of protection against a
second infecting HIV subtype. If we assume that super-infection
occurs in these cases, then it is conceivable that antiviral immunity
evoked by one subtype had insufficient broad protection at the
time of primary infection against a second infecting virus. Indeed
this assumption has been challenged previously by convincing
findings revealing that a second super-infection with a different
HIV-1 strain can occur long after an initial infection is established
and can hasten the disease process [44,45]. Alternatively, the
subjects 010BR_IMT_041 and 010BR_IMT_027 (confirmed
MTCT) may have been vertically and concomitantly infected
with different HIV strains at the same time. On the basis of this
assumption, our results may suggest that despite the genetic
bottleneck occurring upon vertical transmission of HIV-1, the
replication capacity of transmitted variants is not necessarily
reduced. This interpretation is in line with previous studies that
provided evidences of multiple-variant transmission in MTCT,
and also agreed with the conclusion that in a majority of cases the
infant is infected with a single isolate [46,47,48]. By the lack of
mode of transmission in patient 010BR_IMT_020, it was
therefore not possible to interpret the simultaneous detection of
both viruses.
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Our results on genotype resistance mutations are consistent with
previous studies with similar subjects indicating that prevalence of
major mutations conferring ART resistance in viral DNA/RNA of
such chronically infected groups is common (20/38, 52.6%) [34].
In patients with available sequences from the Pro and/or RT, the
mutations found in PBMCs were generally also found in the
plasma, although some of the patients showed few differences
between the two compartments, while in one patient
(010BR_IMT_011) the 69 insertion in the protease region was
found in PBMC, but not in plasma.
Regardless of the sample compartment, the analysis of HIV
tropism revealed two patients with X4 viruses and both with CDC
class ‘‘C3’’ reflecting advanced disease. The assessment of HIV
tropism in our study was limited to sequence- based algorithms
rather than using phenotypic methods. Although phenotypic
assays still have an edge over genotypic methods, genotypic
predictors prove to be highly concordant with phenotype data and
can reliably be used to determine viral tropism with better results
in PBMC than in plasma samples [49]. In this study, we used
geno2pheno, which has shown a similar performance to the
Trofile phenotypic assay, the most often used tropism method
[50]. Moreover, the method has been shown to achieve higher
sensitivity while retaining high level of specificity when compared
with the performance of different algorithms [51,52].
We are aware that the demonstration of the high recombination
rate and evidence of double infections and their association with
virological response and viral tropism should be based on a larger
dataset to establish statistical influence of these factors in
determining the outcome. Another limitation of this study is that
direct bulk sequencing and genotyping of HIV-1 in plasma and
whole blood might underestimate low-level minority species
present as quasispecies which could be evidenced by more complex
methods, such as massive parallel pyrosequencing [53,54,55].
Despite these limitations, the results of this analysis indicate that
HIV-1 recombination and dual infections are much more frequent
than thought previously among children and adolescents in this
region. Evidently, more extensive studies with large sample sizes
are required to unravel the mechanisms underlying the emergence
of these recombinants and their implications for HIV control.
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